Skip to main content
Home
  • About Us
    • About Us
    • Mission & Values
    • Leadership
    • News
    • Careers
    • Partnerships
    • Support
    • Achievements
  • For Researchers
    • Clinical Trials
      • Allergy & Asthma
      • Autoimmune Disease
      • Transplantation
      • Type 1 Diabetes
    • Core Facilities
    • Lab Protocols
      • ITN Protocols
      • T1D Preclinical Consortium
    • Policies
      • Publications Policy
    • Proposals
      • Submit Proposal
      • Current RFPs
      • Past RFPs
    • Publications
    • TrialShare
    • Strategic Plans
      • Allergy
      • Autoimmune Disease
        • Type 1 Diabetes
      • Transplantation
  • For Patients
    • Allergy & Asthma
    • Autoimmune Disease
    • Transplantation
      • Kidney
      • Liver
    • Type 1 Diabetes
    • Clinical Trial Info
  • TrialShare
  • Contact
    • Contact Us
      • BRI - Seattle Office
      • UCSF - San Francisco Office
    • Media Inquiries
Home

Secondary links

  • Home
  • TrialShare
  • Member Portal
  • About Us
    • About Us
    • Mission & Values
    • Leadership
    • News
    • Careers
    • Partnerships
    • Support
    • Achievements
  • For Researchers
    • Clinical Trials
    • Core Facilities
    • Lab Protocols
    • Policies
    • Proposals
    • Publications
    • TrialShare
    • Strategic Plans
  • For Patients
    • Allergy & Asthma
    • Autoimmune Disease
    • Transplantation
    • Type 1 Diabetes
    • Clinical Trial Info
  • TrialShare
  • Contact
    • Contact Us
    • Media Inquiries

Primary links (clinical trials)

  • About Us
    • About Us
    • Mission & Values
    • Leadership
    • News
    • Careers
    • Partnerships
    • Support
    • Achievements
  • For Researchers
    • Clinical Trials
      • Allergy & Asthma
      • Autoimmune Disease
      • Transplantation
      • Type 1 Diabetes
    • Core Facilities
    • Lab Protocols
      • ITN Protocols
      • T1D Preclinical Consortium
    • Policies
      • Publications Policy
    • Proposals
      • Submit Proposal
      • Current RFPs
      • Past RFPs
    • Publications
    • TrialShare
    • Strategic Plans
      • Allergy
      • Autoimmune Disease
      • Transplantation
  • For Patients
    • Allergy & Asthma
    • Autoimmune Disease
    • Transplantation
      • Kidney
      • Liver
    • Type 1 Diabetes
    • Clinical Trial Info
  • TrialShare
  • Contact
    • Contact Us
      • BRI - Seattle Office
      • UCSF - San Francisco Office
    • Media Inquiries

Liver Transplantation with Tregs at MGH and UCSF (LITTMUS)

Principal Investigator

James Markman, MD, PhD | Massachusetts General Hospital | Boston, MA;
Sandy Feng, MD, PhD | University of California San Francisco | San Francisco, CA

Locations

Massachusetts General Hospital | Boston, MA
University of California San Francisco | San Francisco, CA

Study Code

ITN073ST; ITN074ST

Study Status

Active

Abstract

LITTMUS is comprised of two single-center, prospective, open-label, non-randomized clinical trials exploring cellular therapy to facilitate immunosuppression withdrawal in liver transplant recipients. One of the trials will take place at Massachusetts General Hospital in Boston, MA and the other will take place at UCSF in San Fransico, CA.

The primary objective of the LITTMUS studies is to evaluate the safety and efficacy of a single IV dose of autologous, donor alloantigen-specific T regulatory cell (arTreg) product to induce operational tolerance following living or deceased donor liver transplantation. 

LITTMUS will test a new approach to achieve transplant tolerance using the liver transplant recipient’s own T regulatory cells (Tregs) to produce donor alloantigen-specific Tregs. Donor alloantigen-specific Tregs are the primary investigational product in this study. Participants who successfully recieve arTregs and who successfully withdraw from immunosuppression will be closely followed for 2 years in order to monitor for any signs of transplant rejection.

About This Study

LITTMUS is a clinical research study testing a new approach to achieve transplant tolerance using the liver transplant recipient’s own T regulatory cells (Tregs).

The goal of the LITTMUS study is to find out:

  1. Whether Tregs are safe to use after liver transplantation
  2. Whether Tregs can allow liver transplant recipients to take less or even stop anti-rejection medication without causing liver damage  

Tregs are normally present in very low numbers and act as the brakes on the immune system. In this study, we will take cells from the recipient’s blood and cells from the living or deceased liver donor. Then we will use these cells in the laboratory to grow Tregs and find out if these Tregs can be used to protect the transplanted liver. These cells will be given to recipients only if both recipients and their living donors (if applicable) are doing well after transplant. After the study Tregs are administered, we will try to slowly reduce and possibly stop anti-rejection medications.

Liver transplant recipients who take part in this study and are able to stop all anti-rejection medications without harming their transplanted liver, will have achieved tolerance. We do not know whether anyone participating in this study will achieve tolerance. It is reported that a small percentage of liver transplant recipients may become tolerant without undergoing any special medical treatment.

We think that being off anti-rejection medications might be good in the long run because of their known side effects. However, we don’t know if the potential benefits of being off these medications outweigh the risks. The main risk of not taking anti-rejection medications is rejection of the liver. We will be monitoring study participants very closely to catch any signs of rejection early so that we can treat it and keep participants and their livers healthy.

[Clinicaltrials.gov] [Study Website]

Do you Qualify for this Clinical Trial?

Eligible participants for the LITTMUS study will:

  • Be 18 years of age or older
  • Be candidates for a liver transplant
  • Not have received a previous organ, tissue, or cell transplant
  • Not have active hepatitis C (HCV) or a history of human immunodeficiency virus (HIV)

To learn more about this study and participant eligibility, please visit the study website: LittmusStudy.org.

Principal Investigator

James Markman, MD, PhD | Massachusetts General Hospital | Boston, MA;
Sandy Feng, MD, PhD | University of California San Francisco | San Francisco, CA

Locations

Massachusetts General Hospital | Boston, MA
University of California San Francisco | San Francisco, CA

Contact a study site near you.

The Immune Tolerance Network and is sponsored by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

National Institute of Allergy and Infectious Diseases

Footer

  • Home
  • Sponsors
  • Careers
  • Contact
  • Search

© 2021 Immune Tolerance Network

  • Privacy
  • Terms of Use
  • Accessibility